A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets. Our pharmaceutical business features NGENLA® (somatrogon-ghla), also referred to as Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for further development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of children and adolescents as young as three years of age with growth disturbance due to insufficient secretion of growth hormone, have been secured in more than 50 markets worldwide, including in the United States, European Union Member States, Japan, Canada, and Australia under the brand name NGENLA®. Through our pharmaceutical business, we manufacture and sell Rayaldee, a U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 607M | 607M | 713M | 863M | 1.0B | 1.8B |
| Net Income | -226M | -226M | -53M | -189M | -328M | -30M |
| EPS | $-0.30 | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 |
| Free Cash Flow | -191M | -191M | -208M | -44M | -120M | 6.2M |
| ROIC | -9.4% | -16.7% | -3.5% | -13.5% | -20.9% | 1.0% |
| Gross Margin | 33.9% | 33.9% | 30.6% | 36.8% | 28.7% | - |
| Debt/Equity | 0.07 | 0.07 | 0.13 | 0.03 | 0.03 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -117M | -117M | -152M | -157M | -226M | 19M |
| Operating Margin | -19.3% | -19.3% | -21.3% | -18.2% | -22.5% | 1.1% |
| ROE | -17.8% | -17.1% | -3.9% | -12.8% | -20.2% | -1.8% |
| Shares Outstanding | 752M | 752M | 665M | 755M | 714M | 603M |
OPKO HEALTH, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 32.5%. Total shareholder yield (buybacks) is 5.3%.
OPKO HEALTH, INC. (OPK) has a 5-year average return on invested capital (ROIC) of -10.7%. This is below average and may indicate limited pricing power.
OPKO HEALTH, INC. (OPK) has a market capitalization of $880M. It is classified as a small-cap stock.
OPKO HEALTH, INC. (OPK) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.34%.
OPKO HEALTH, INC. (OPK) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
OPKO HEALTH, INC. (OPK) reported annual revenue of $607 million in its most recent fiscal year, based on SEC EDGAR filings.
OPKO HEALTH, INC. (OPK) has a net profit margin of -37.2%. The company is currently unprofitable.
OPKO HEALTH, INC. (OPK) generated $-191 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
OPKO HEALTH, INC. (OPK) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
OPKO HEALTH, INC. (OPK) reported earnings per share (EPS) of $-0.30 in its most recent fiscal year.
OPKO HEALTH, INC. (OPK) has a return on equity (ROE) of -17.1%. A negative ROE may indicate losses or negative equity.
OPKO HEALTH, INC. (OPK) has a 5-year average gross margin of 32.5%. This indicates decent pricing power.
The Ledger Terminal provides 17 years of financial data for OPKO HEALTH, INC. (OPK), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
OPKO HEALTH, INC. (OPK) has a book value per share of $1.69, based on its most recent annual SEC filing.